In 2012, the cost of caring for Americans with Alzheimer’s totaled approximately $200 billion, and Medicare and Medicaid picked up a hefty portion of this bill. This number is expected to soar to $1.1 trillion by 2050. Recognizing the heavy burden of this disease, the President’s Fiscal Year 2013 Budget request to Congress included $100 million to support Alzheimer’s research, public awareness and family caregiver support. This session will look at the role federal agencies, including NIH, FDA and CMS, are playing to help accelerate the development of breakthrough treatments to help prevent, stop or reverse the course of Alzheimer’s disease. Recent efforts will be highlighted, including the National Alzheimer’s plan, identification of targets emerging from the National Center for Advancing Translational Research, repurposing of compounds and access to and coverage for diagnostics, among other topics

Learning Objectives:

  • Review creative solutions to overcome obstacles around treatment and care for patients living with Alzheimer’s disease
  • Discuss the current priorities set forth by federally funded programs and the state of the National Alzheimer’s plan
  • Explore how public-private collaborations can help improve health outcomes and quality care for people with Alzheimer’s disease

Ability Level: All

Session ID: 2108

myBIO Chatter

Speakers (4)

contact_10080 Dora Hughes Senior Policy Advisor Sidley Austin LLP
contact_10185 Rachel Lane, PhD Assistant Director, Scientific Affairs Alzheimer's Drug Discovery Foundation
User Soeren Mattke, D.Sc., M.P.H., MD Managing Director, RAND Health Advisory RAND Corporation
contact_10012 Heather Snyder, PhD Director, Medical and Scientific Relations Alzheimer's Association